(AOF) – Smaio announces a turnover up 120% in 2023, to 5.4 million euros. This specialist in complex spinal surgery with an offering made up of software, implantable devices and associated services, specifies that this increase is driven by the milestone payment of $3 million from NuVasive during the first half of 2023 and the acceleration of sales of the Kheiron system in the fourth quarter of 2023 (+40% year-on-year).
“Obtaining 510(k) certification by the FDA on the personalized version of our surgical planning software was an important first milestone, allowing us to receive the payment of 3 million dollars from our American partner , NuVasive”, specifies boss Philippe Roussouly.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.